CN111228366B - Traditional Chinese medicine composition for treating viral pneumonia - Google Patents
Traditional Chinese medicine composition for treating viral pneumonia Download PDFInfo
- Publication number
- CN111228366B CN111228366B CN202010192144.7A CN202010192144A CN111228366B CN 111228366 B CN111228366 B CN 111228366B CN 202010192144 A CN202010192144 A CN 202010192144A CN 111228366 B CN111228366 B CN 111228366B
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- medicine composition
- drugs
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating viral pneumonia, which comprises tribulus terrestris and honeysuckle as monarch drugs, and isatis root, scutellaria baicalensis and patrinia as ministerial drugs. The traditional Chinese medicine composition for treating viral pneumonia can effectively treat new coronary pneumonia, has a remarkable curative effect in treating the new coronary pneumonia, can prevent patients from getting worse, is convenient for a large number of patients to use simultaneously as a general prescription, and wins time for patients to treat and take medicines early.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition (Bai jin Dan) for treating viral pneumonia.
Background
The new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) is abbreviated as new coronavirus pneumonia, and is pneumonia caused by 2019 new coronavirus infection. The clinical manifestations of patients with pneumonia infected by the novel coronavirus are: fever, hypodynamia, dry cough, nasal obstruction, watery nasal discharge and other symptoms of the upper respiratory tract are rare, and hypoxia occur [12 ]. Approximately half of patients develop dyspnea after one week, and severe patients rapidly progress to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, and procoagulant dysfunction. It is noted that the severe and critically ill patients may have moderate or low fever during their course, even without significant fever. Some patients have mild onset symptoms and no fever, and recover after 1 week. The prognosis is good for most patients, and the disease is critical or even death for a few patients.
After the outbreak of the epidemic situation of pneumonia infected by the novel coronavirus, the national defense and health committee publishes a novel diagnosis and treatment scheme for pneumonia of the coronavirus, and by analyzing the situation of the epidemic situation and the research progress, an organization expert timely revises the diagnosis and treatment scheme on the basis of analyzing, researching and judging and summarizing early-stage medical treatment work. However, no good effective therapeutic drug for the new coronary pneumonia exists at present.
The traditional Chinese medicine has the curative effects of relieving fever symptoms of the new coronary pneumonia, controlling the progress of diseases, reducing the dosage of hormones, relieving complications and the like. Traditional Chinese medicine treatment usually aims at diseases, but mobilizes the disease resistance of the organism, and has unique advantages in the aspects of improving clinical symptoms, reducing complications, improving life quality and the like.
Disclosure of Invention
The invention aims to solve the technical problem that the novel coronavirus pneumonia in the prior art does not have a good treatment medicine, and aims to provide a traditional Chinese medicine composition for treating viral pneumonia, in particular to novel coronavirus (COVID-19) pneumonia, namely a Baijin Dan. The traditional Chinese medicine composition can prevent pulmonary fibrosis and pulmonary nodules of cured patients.
The traditional Chinese medicine composition for treating viral pneumonia comprises tribulus terrestris and honeysuckle as monarch drugs, and isatis root, scutellaria baicalensis and patrinia as ministerial drugs.
Preferably, the Chinese medicinal composition also comprises radix bupleuri or rhizoma Osmundae as ministerial medicaments.
Preferably, the Chinese medicinal composition further comprises caulis Polygoni Multiflori or radix Polygoni Multiflori as adjuvant drug.
Preferably, the Chinese medicinal composition further comprises angelica, salvia miltiorrhiza or red paeony root as an adjuvant drug.
Preferably, the Chinese medicinal composition also comprises almond as an adjuvant and a guiding drug.
In a preferred embodiment of the invention, 2-20 g of tribulus terrestris, 3-30 g of honeysuckle, 3-60 g of isatis root, 3-25 g of scutellaria baicalensis and 3-60 g of herba patriniae are taken as parts by weight; preferably, 8-17 g of tribulus terrestris, 10-20 g of honeysuckle, 7-15 g of isatis root, 8-15 g of scutellaria baicalensis and 10-15 g of herba patriniae.
Preferably, the traditional Chinese medicine also comprises 3-25 g of radix bupleuri or 5-50 g of cyrtomium rhizome; preferably 8-15 g of bupleurum or 10-15 g of cyrtomium rhizome.
Preferably, 5-60 g of caulis polygoni multiflori or 3-30 g of raw fleece-flower root is also included; preferably 8-15 g of caulis polygoni multiflori and 8-15 g of raw fleece-flower root.
Preferably, 3-30 g of angelica, 4-40 g of salvia miltiorrhiza or 3-50 g of red paeony root is also included; preferably 10-15 g of angelica, 10-17 g of salvia miltiorrhiza or 8-15 g of red peony root; preferably, the almond also comprises 2-25 g of almond, preferably 8-17 g of almond.
Preferably, the viral pneumonia is new coronavirus (COVID-19) pneumonia. The traditional Chinese medicine composition is decoction, tablets or granules.
The traditional Chinese medicine composition for treating viral pneumonia consists of thirteen traditional Chinese medicines, namely tribulus terrestris, honeysuckle, salvia miltiorrhiza, angelica, red paeony root, almond, radix bupleuri, cyrtomium rhizome, isatis root, raw fleece-flower root, scutellaria baicalensis, patrinia and tuber fleeceflower stem. The traditional Chinese medicine composition for treating viral pneumonia has the effects of dispelling wind, relieving exterior syndrome, clearing plague, expelling toxin, promoting blood circulation, eliminating turbid pathogen, cooling blood and clearing orifices. In the traditional Chinese medicine composition, the tribulus terrestris is used for dispelling wind, resolving stagnation and expelling surficial evils, and the honeysuckle is used for dispelling wind, clearing heat and detoxifying. Radix bupleuri has the effects of promoting the circulation of exterior and expelling heat, soothing liver and relieving depression, and lifting yang qi, cyrtomium rhizome and isatis root have the effects of clearing heat and removing toxicity, radix scutellariae has the effects of clearing heat, eliminating dampness and removing toxicity, and herba patriniae has the effects of removing blood stasis, resolving masses and expelling toxin to treat large intestine (the lung and the large intestine are exterior and interior), and the five drugs are used as ministerial drugs together. Caulis Polygoni Multiflori is effective in nourishing heart, tranquilizing mind, dispelling pathogenic wind, dredging collaterals, and nourishing liver and kidney essence and blood, and can balance yin and yang, and relieve excessive struggle between vital qi and pathogenic factors. Chinese angelica can tonify blood and activate blood, and both deficiency and excess can be used; salvia miltiorrhiza, which is cool in nature and is especially suitable for blood heat and stasis, promotes blood circulation to remove meridian obstruction; the red peony root moves and disperses, cools blood and clears heat, and clears away toxic materials; bitter apricot seeds, semen Armeniacae amarum, with the actions of purging and descending qi and relieving asthma, are used as adjuvant and assistant for the assistant, monarch, minister and concurrent treatment of diseases. The lung meridian and large intestine meridian entered by xing ren are both guiding and guiding herbs. The monarch, minister, assistant and guide can coordinate with each other, and the lung-protecting and whole-body-protecting effects can be achieved.
The positive progress effects of the invention are as follows: the traditional Chinese medicine composition for treating viral pneumonia can effectively treat new coronary pneumonia, has a remarkable curative effect in treating the new coronary pneumonia, and can prevent patients from getting worse; in addition, hormone is not needed in the treatment process, and pulmonary fibrosis and pulmonary nodules of patients cured by the traditional Chinese medicine composition are avoided. As the traditional Chinese medicine composition is used as a general prescription, a large number of patients can use the traditional Chinese medicine composition at the same time, and the time for the patients to treat and take medicine in an early stage is gained. Because the general prescription does not need to carry out four diagnoses of inspection, smelling, inquiry and cutting on each patient; under the condition of shortage of doctors, timely treatment of patients is not influenced, and the risk of infection of doctors is reduced when the protection condition is poor; the operation is simple and convenient, training is not needed, and when the sickbed is insufficient in the traditional method, the light patient can be treated in a separated mode at home. The traditional Chinese medicine composition for treating viral pneumonia is low in price and low in medical cost.
The conception, the specific structure, and the technical effects produced by the present invention will be further described below to fully understand the objects, the features, and the effects of the present invention.
Drawings
FIG. 1A is a photograph of a chest radiograph of a patient A infected with new crown pneumonia before the treatment with the Chinese medicinal composition of example 1 of the present invention, i.e., the treatment of 2020, 01, 27 (abnormal appearance in the circle);
FIG. 1B is a photograph of a chest radiograph taken at 02/17 of 2020 after a patient A infected with neocoronary pneumonia is treated with the Chinese medicinal composition of example 1 of the present invention (the circle shows improvement);
FIG. 2A is a photograph of a chest radiograph taken before a patient B infected with new crown pneumonia is treated with the Chinese medicinal composition of the present invention in example 2, i.e., in 2020, month 02 and day 04 (abnormal appearance in the circle);
FIG. 2B is a photograph of a chest radiograph taken at 18/02/2020 after a patient B infected with neocoronary pneumonia is treated with the Chinese medicinal composition of example 2 of the present invention (the circle shows improvement);
FIG. 3A is a photograph of a chest radiograph taken before a patient C infected with new crown pneumonia is treated with the Chinese medicinal composition of the present invention in example 3, i.e., in 2020, month 02 and day 04 (abnormal appearance in the circle);
FIG. 3B is a photograph of a chest radiograph taken at 02/16 of 2020 after a patient C infected with neocoronary pneumonia is treated with the Chinese medicinal composition of example 3 of the present invention (the circle shows improvement);
fig. 4A is a chest radiography (abnormal representation in circles) of a patient D infected with new coronary pneumonia before treatment with the Chinese medicinal composition of the present invention in example 4, i.e., day 01, month 27 in 2020;
FIG. 4B is a photograph of a chest radiograph taken at 02/17 of 2020 after a patient D infected with neocoronary pneumonia is treated with the Chinese medicinal composition of example 4 of the present invention (the circle shows improvement);
FIG. 5A is a photograph of a chest radiograph taken on day 04 of month 02 of 2020 (shown as abnormal) of a patient E infected with neocoronary pneumonia before treatment with the Chinese medicinal composition of example 5 of the present invention;
fig. 5B is a photograph of a chest radiography (the circle shows improvement) of a patient E infected with new coronary pneumonia after being treated with the Chinese medicinal composition of the present invention in example 5 at month 18 and 02 of 2020.
Detailed Description
EXAMPLES 1-6 Chinese medicinal composition and preparation thereof
TABLE 1 raw material formulation of Chinese medicinal composition of examples 1-6
The raw material formulations of examples 1-6 were decocted as follows, and poured into a casserole container according to the formulation in table 1, with water approximately one inch above the Chinese herbal medicine. Soaking for 40 min, boiling with strong fire, turning to slow fire, and decocting with slow fire for 20 min. After cooking, pour into bowl. Adding water again, boiling with strong fire until the water is over the traditional Chinese medicines, turning to a small pot, boiling with slow fire for 25 minutes, and pouring into the same bowl. The Chinese medicinal composition, namely the Chinese medicinal compound decoction, is prepared.
Effect examples 1 to 6
43 patients with hospitalized new coronary pneumonia in traditional Chinese medicine institute of Songzi, Hubei province were treated with the Chinese medicinal compositions of examples 1-6.
The 43 patients were as follows:
sex: 27 men; female 16 people.
Age: 0 persons under 10 years of age; 11-20 years old 2 people; 6 persons 21-30 years old;
7 persons 31-40 years old; 10 persons of age 41-50 years old; 8 persons 51-60 years old;
6 persons 60-70 years old; 4 persons over 70 years old. A minimum of 12 years old; max 81 years old.
According to the fourth edition of the national Wei-Jian-Wei-Jian-Wei-Xin coronary pneumonia diagnosis and treatment scheme, 43 patients all meet the requirements of diagnosis standards, wherein: 20 confirmed cases and 23 suspected cases were diagnosed.
38 persons of the common type; 5 persons with heavy weight; the patient is at risk for 0 person.
The treatment scheme comprises the following steps: the 43 cases were treated with the Chinese medicinal composition of examples 1-6, and were orally administered three times a day, 1/3 doses each time. And supported treatment was performed 2 times daily using a 5% glucose injection or a 500mL intravenous titration with 0.9% sodium chloride injection.
TABLE 2 number of cases of patients treated with the Chinese medicinal composition of examples 1 to 6
The treatment effect is as follows: the disease development of the patient is controlled, severe and critical conditions do not occur, and the patient is completely cured. According to the discharge standard specified by the State health and institutional Commission, 43 patients are discharged after reaching the standard. When all patients are discharged, the body temperature returns to normal for more than 3 days, respiratory symptoms are obviously improved, pulmonary imaging shows that inflammation is obviously absorbed, and the respiratory pathogenic nucleic acid detection is negative continuously twice (the sampling time interval is at least 1 day). 43 patients are discharged from the hospital, and the shortest hospitalization time is 16 days; the longest stay in hospital is 22 days; 0 cases of death; average hospital stay was 18.6 days. CT photographs of 5 typical patients A-D before and after treatment with the Chinese medicinal composition of examples 1-5 are shown in FIGS. 1A, 1B to 5A, 5B.
The pathogenesis and course of the new coronary pneumonia are analyzed: the invasion of the virus determines the state of illness or the severity of the patient according to the virus load, the toxicity and the immunity of the patient; an over-stimulated immune response caused by inflammatory factors released by cells invaded by viruses causes a large amount of lung cell damage and inflammatory product aggregation, so that 'white lung' occurs, and lung function failure is caused, which is the root cause of death; after the critical period, the pulmonary tissue cell architecture is rebuilt, the microcirculation is gradually recovered, the ventilation function is recovered, and the process is slow, so severe and critical patients can not be discharged for a long time; the new coronary pneumonia is a self-limiting disease, and can be cured after a certain time under the intervention of effective medicines.
The traditional Chinese medicine composition has an antiviral function, and can inhibit a large amount of viruses from being copied; inhibiting autoimmune reaction, relieving inflammation storm, and preventing rapid enlargement of lung leukosis; the frosty glass-shaped lesion generated in the lung is reversed, the pulmonary microcirculation is opened, the reconstruction of the lung group cell architecture is promoted, and the ventilation function of the lung is gradually recovered; the traditional Chinese medicine composition disclosed by the invention is composed of tribulus terrestris, honeysuckle, salvia miltiorrhiza, cyrtomium rhizome, almond and the like, and has the effects of dispelling wind, relieving exterior syndrome, clearing pestilence, expelling toxin, dredging, eliminating turbid pathogen, cooling blood and clearing orifices. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition can play the roles in the occurrence and development of diseases simultaneously, and has no rare medicinal materials, low cost, convenient operation and no obvious side effect after being taken by a plurality of patients.
Claims (2)
1. A traditional Chinese medicine composition for treating novel coronavirus COVID-19 pneumonia is characterized by being prepared from the following monarch drugs, ministerial drugs, adjuvant drugs and conductant drugs: tribulus terrestris and honeysuckle are used as monarch drugs, and isatis root, scutellaria baicalensis, patrinia, radix bupleuri and cyrtomium rhizome are used as ministerial drugs; caulis Polygoni Multiflori, radix Angelicae sinensis, radix Salviae Miltiorrhizae, and radix Paeoniae Rubra as adjuvant drugs; the almond is used as an adjuvant and a guiding drug;
8-17 g of tribulus terrestris, 10-20 g of honeysuckle, 7-15 g of isatis root, 8-15 g of scutellaria baicalensis, 10-15 g of patrinia, 8-15 g of radix bupleuri, 10-15 g of cyrtomium rhizome, 8-15 g of tuber fleeceflower stem, 8-15 g of raw fleece-flower root, 10-15 g of angelica, 10-17 g of salvia miltiorrhiza, 8-15 g of red paeony root and 8-17 g of almond.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition is a decoction, a tablet or a granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010192144.7A CN111228366B (en) | 2020-03-18 | 2020-03-18 | Traditional Chinese medicine composition for treating viral pneumonia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010192144.7A CN111228366B (en) | 2020-03-18 | 2020-03-18 | Traditional Chinese medicine composition for treating viral pneumonia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111228366A CN111228366A (en) | 2020-06-05 |
CN111228366B true CN111228366B (en) | 2021-08-31 |
Family
ID=70867430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010192144.7A Active CN111228366B (en) | 2020-03-18 | 2020-03-18 | Traditional Chinese medicine composition for treating viral pneumonia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111228366B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579467A (en) * | 2003-08-12 | 2005-02-16 | 杨荣 | Anti-virus medicine |
CN1650912A (en) * | 2004-02-05 | 2005-08-10 | 上海国圣医疗科技有限公司 | Chinese medicinal preparation for treating lung fibrosis |
-
2020
- 2020-03-18 CN CN202010192144.7A patent/CN111228366B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1579467A (en) * | 2003-08-12 | 2005-02-16 | 杨荣 | Anti-virus medicine |
CN1650912A (en) * | 2004-02-05 | 2005-08-10 | 上海国圣医疗科技有限公司 | Chinese medicinal preparation for treating lung fibrosis |
Non-Patent Citations (1)
Title |
---|
中药祛疣散治疗传染性软疣;郑振民;《中国民间疗法》;19951231(第4期);第22页,左栏第1-2段 * |
Also Published As
Publication number | Publication date |
---|---|
CN111228366A (en) | 2020-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110870402A (en) | Prescription for treating pneumonia infected by novel coronavirus and application thereof | |
CN111265616B (en) | Traditional Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia | |
CN111265586B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
CN111388582B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
CN111671867B (en) | Novel traditional Chinese medicine composition for treating mild coronary virus pneumonia cough | |
CN111298049A (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
CN111249390A (en) | Forsythia-astragalus root compound preparation and preparation method and application thereof | |
CN111110819A (en) | Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza | |
CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
CN111228366B (en) | Traditional Chinese medicine composition for treating viral pneumonia | |
CN106138668A (en) | A kind of Chinese medicine composition treating COPD and preparation method thereof | |
CN113350429B (en) | Traditional Chinese medicine composition for preventing and treating African swine fever disease as well as preparation method and application thereof | |
CN115919963A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating novel coronavirus infection | |
CN111184805B (en) | Traditional Chinese medicine composition and application thereof | |
CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
CN104274706A (en) | Traditional Chinese medicine mixture for treating radioactive stomatitis | |
CN116036202B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, and preparation method and application thereof | |
CN111375036B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
CN113274470B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia | |
CN114569690B (en) | Traditional Chinese medicine composition for treating helicobacter pylori infectious gastritis | |
CN116492432B (en) | Traditional Chinese medicine mixture for treating lung syndrome caused by pathogenic heat of virus infection | |
CN101637533B (en) | Application of Chinese medicinal composition in preparation of medicament for treating virus myocarditis | |
CN103028088B (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |